Abstract
Background
Abdominal pain/discomfort, bloating, and constipation are gastrointestinal dysmotility and sensory symptoms associated with irritable bowel syndrome (IBS). No studies have followed patients with IBS symptoms for 1 year under conditions of routine clinical practice to assess prospectively the impact of treatments on health outcomes.Objective
The objective of this ongoing, naturalistic study is to assess the long-term impact of IBS treatments on quality of life (QOL), work productivity, and resource utilization. This report describes the baseline characteristics and patterns of care of the patients enrolled in this study.Methods
Patients with physician-diagnosed IBS symptoms were enrolled from 147 physician sites across Canada between May 4, 2004, and March 31, 2005. Clinical data were collected at baseline and at the end of the 12-month follow-up (patients were followed for 1 year between May 4, 2005, and March 31, 2006). Patient-reported outcomes were collected at baseline and at months 1, 2, 6, 9, and 12. Health-related QOL, health status, and work productivity were assessed with the IBS-QOL, a 5-item EuroQol descriptive system, and Work Productivity and Activity Impairment questionnaires, respectively. A resource utilization questionnaire elicited information on physician; visits, treatments, and procedures. Baseline data are reported here.Results
Data were obtained from 1555 patients; 85.1% (1320/1552) were women. Patients had a mean (SD) age of 45.8 (15.0) years and mean (SD) duration of IBS symptoms of 11.4 (11.5) years. Self-reported bowel patterns were predominantly constipation (41.0%, 587/1433) and constipation alternating with diarrhea (39.4%, 564/1433); 60.3% (938/1555) of subjects used > or =3 IBS treatments in the previous 4 weeks. Approximately 50% of all patients reported distress "quite a bit or "extremely" for abdominal pain, gas, bloating, and constipation. The mean overall IBS-QOL score (0-100 scale, with 0 indicating poor QOL) was 66.3; food avoidance (51.8) and health worry (59.3) were the most serious concerns. Patients reported 5.6% work absenteeism, 31.4% presenteeism, and 34.6% overall work productivity loss, equivalent to 13.8 hours lost productivity per 40-hour workweek.Conclusions
The baseline data from this ongoing, prospective, naturalistic study are consistent with previous findings that suggested significant use of health care resources with concomitant low QOL and decreased work productivity in patients with IBS symptoms.References
Articles referenced by this article (49)
Evidence-based position statement on the management of irritable bowel syndrome in North America
Am J Gastroenterol, (Suppl 11):S1- 2002
Irritable bowel syndrome in office-based practice in the United States.
Gastroenterology, (4):998-1005 1991
MED: 2001837
Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates.
Dig Dis Sci, (9):1581-1589 1993
MED: 8359067
Survey of the AGA membership relating to patients with functional gastrointestinal disorders.
Gastroenterology, (5 Pt 1):1282-1284 1987
MED: 3557021
Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire.
Dig Dis Sci, (1):225-235 2002
MED: 11837727
Clinical economics review: gastrointestinal disease in primary care.
Aliment Pharmacol Ther, (3):233-239 1996
MED: 8791945
Impairment in work productivity and health-related quality of life in patients with IBS
Am J Manag Care, (Suppl 1):S17- 2005
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases.
Clin Ther, (4):675-89; discussion 674 2002
MED: 12017411
Show 10 more references (10 of 49)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1016/j.clinthera.2006.10.010
Article citations
A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.
Gastroenterol Hepatol (N Y), 20(7):383-427, 01 Jul 2024
Cited by: 0 articles | PMID: 39206030 | PMCID: PMC11348549
Challenges of recruitment processes to a randomized dietary trial in irritable bowel syndrome.
F1000Res, 13:323, 24 Jun 2024
Cited by: 2 articles | PMID: 38939366
Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature review.
Biopsychosoc Med, 18(1):12, 15 May 2024
Cited by: 0 articles | PMID: 38750514 | PMCID: PMC11094939
Review Free full text in Europe PMC
Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease.
Dig Dis Sci, 69(5):1626-1635, 24 Feb 2024
Cited by: 0 articles | PMID: 38400884 | PMCID: PMC11098900
The Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter].
Clin Epidemiol, 16:7-8, 16 Jan 2024
Cited by: 0 articles | PMID: 38250453 | PMCID: PMC10799645
Go to all (120) article citations
Other citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Longitudinal Outcomes of GastroIntestinal symptoms in Canada (LOGIC): key factors for an effective patient retention in observational studies.
Can J Clin Pharmacol, 16(1):e140-50, 31 Jan 2009
Cited by: 0 articles | PMID: 19182307
Impairment in work productivity and health-related quality of life in patients with IBS.
Am J Manag Care, 11(1 suppl):S17-26, 01 Apr 2005
Cited by: 111 articles | PMID: 15926760
Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation.
J Psychosom Res, 64(2):129-138, 01 Feb 2008
Cited by: 28 articles | PMID: 18222126
Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Eur J Gastroenterol Hepatol, 19(12):1097-1103, 01 Dec 2007
Cited by: 36 articles | PMID: 17998835
Review